Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation

Okishige, Kaoru; Yamauchi, Yasuteru; Hanaki, Yuichi; Inoue, Koichi; Tanaka, Nobuaki; Yamaji, Hirosuke; Murakami, Takashi; Manita, Mamoru; Tabata, Kazuhiro; Ooie, Tatsuhiko; Tatsukawa, Youichi; Sakai, Hirotsuka; Yamaki, Masaru; Murakami, Masato; Takada, Takuma; Osaka, Yuki; Ono, Yūichi; Handa, Keita; Sugiyama, Koji; Yoshizawa, Tomoharu; Fukaya, Hidehira; Tashiro, Hironori; Takase, Susumu; Harada, Masahide; Watanabe, Eiichi; Yamane, Teiichi; Yamashita, Seigo; Aonuma, Kazutaka

doi:10.1007/s11239-019-01835-8

Cited by 14 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiac tamponade is a potentially fatal complication and is among the most frequently observed complications of catheter ablation [19]. Although the results of the RE-CIRCUIT study [20] show the benefit of uninterrupted anticoagulation with dabigatran during catheter ablation, administration of idarucizumab might also be useful for patients with cardiac tamponade, as demonstrated in an idarucizumab case series in Japan [21]. In a retrospective analysis of 21 patients with cardiac tamponade who received idarucizumab, hemostasis was restored at a median of 205.6 ± 14.8 min, and no thromboembolic events had occurred within 72 h after the idarucizumab administration [21].…”

Section: Discussionmentioning

confidence: 99%

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The management of anticoagulation therapy during the peri-catheter ablation period has been rewritten because various important clinical evidence has been documented in both Japan and abroad, [12][13][14][15][16][17][18] and because a supplemental description was needed according to the contents of the Guidelines on non-pharmacotherapy of cardiac arrhythmias (JCS/JHRS 2019). 6…”

Section: Perioperative Anticoagulation Therapy For Af Ablationmentioning

confidence: 99%

JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

Nogami¹,

Kurita²,

Kusano³

et al. 2022

Journal of Arrhythmia

Self Cite

View full text Add to dashboard Cite

“…Our preliminary experience suggested that ablation with uninterrupted agents was safe and feasible in selected AF patients aged ≥80 years. With the application of specific antagonists for NOACs, we are more confident to adopt an uninterrupted anticoagulation strategy 24 …”

Section: Discussionmentioning

confidence: 99%

“…With the application of specific antagonists for NOACs, we are more confident to adopt an uninterrupted anticoagulation strategy. 24 Whether the use of contact force sensing catheters can reduce the incidence of pericardial tamponade in AF ablation is still in controversy. 17 Earlier study had reported that pericardial tamponade was more likely to occur in the elderly 25 ; in Yanagisawa et al's study, pericardial tamponade was noted in 1.5% of the patients aged ≥75 years during uninterrupted anticoagulation AF procedure.…”

Section: Procedural Safety In Patients Aged ≥80 Yearsmentioning

confidence: 99%

Clinical efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in patients aged ≥80 years

Zhou

Cai

et al. 2020

Pacing Clinical Electrophis

View full text Add to dashboard Cite

Aim: To evaluate the clinical safety and efficacy of radiofrequency catheter ablation for atrial fibrillation (AF) in patients aged ≥80 years. Methods: A total of 333 AF patients aged ≥60 years were enrolled, who underwent contact forceguided radiofrequency catheter ablation with uninterrupted anticoagulation. All patients were followed-up for at least 12 months. Success was defined by the absence of episodes of AF/atrial tachycardia lasting more than 30 seconds after a 3-month blanking period, without antiarrhythmic drugs. Results: Compared to patients aged 60-79 years (Group 2, n = 244), patients aged ≥80 years (Group 1, n = 89) were presented with higher rate of diabetes (36.0% vs 22.1%, P = .011), lower body mass index (23.4 ± 3.1 vs 24.9 ± 3.4 kg/m 2 , P = .001), lower creatinine clearance (56.9 ± 16.5 vs 83.3 ± 24.5 mL/min, P < .001), higher CHA 2 DS 2-VASc score (4.3 ± 1.3 vs 3.3 ± 1.4, P < .001), and HAS-BLED score (2.2 ± 0.8 vs 1.8 ± 0.8, P < .001). Wide antral pulmonary vein isolation was achieved in all patients, and there was no significant difference in procedure time, ablation time, fluoroscopy time, and complications rate between two age groups (P > .05). After a mean followup of 24.4 ± 9.6 months, the overall success rate was 78.2% in Group 1 and 78.9% in Group 2 (P = .622). Conclusions: Radiofrequency ablation with contact force sensing catheters for AF is safe and effective in selected patients aged ≥80 years.

show abstract

Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation

Cited by 14 publications

References 26 publications

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

JCS/JHRS 2021 guideline focused update on non‐pharmacotherapy of cardiac arrhythmias

Clinical efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in patients aged ≥80 years

Contact Info

Product

Resources

About